Uscom Limited (UCM) AI Stock Analysis

• Market Cap: AU$5.01M
• Dividend Yield: N/A
• Average Volume (3M): 134.56K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.53
• Revenue Growth: 2.91%
• EPS Growth: 13.51%
• Country: AU
• Employees: 35
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 250,477,000
• 10 Day Avg. Volume: 372,181
• 30 Day Avg. Volume: 134,558
• PEG Ratio: 0.07
• Price to Book (P/B): 1.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

Uscom Limited's overall stock score reflects its primary challenges in financial performance and valuation. While the company shows revenue growth, ongoing profitability issues, negative cash flow, and a concerning valuation significantly impact the score. The technical analysis remains neutral, providing no strong indication of momentum.

Uscom Limited Business Overview & Revenue Model

Company Description

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company also provides the SpiroSonic AIR, a digital multipath ultrasonic spirometer with a viral disinfection system for the elimination of COVID and tuberculosis; and respiratory devices. It serves hospitals and other medical care locations through a network of distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.

How the Company Makes Money

Uscom Limited generates revenue through the sale of its medical devices to hospitals, clinics, and healthcare providers globally. The company also earns income from service contracts, maintenance agreements, and software upgrades associated with its products. Key revenue streams include direct sales, distributor partnerships, and government contracts, which help expand its market reach. Additionally, Uscom may benefit from strategic collaborations with research institutions and healthcare organizations, further enhancing its product offerings and market penetration.

Uscom Limited Financial Statement Overview

Summary

Uscom Limited shows revenue growth but faces significant profitability challenges with consistently negative EBIT and net income. The balance sheet indicates manageable leverage but declining equity ratios, while cash flow issues persist with negative free cash flow.

Income Statement

Uscom Limited shows a fluctuation in its revenue, with a notable increase in the recent year. However, the company has consistently reported negative EBIT and net income, indicating ongoing profitability challenges. While the gross profit has improved, the net profit margin remains negative, which is a significant concern.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio, suggesting manageable leverage levels. However, the equity ratio has been declining, indicating potential risks in asset management. The return on equity has been negative, highlighting the company's struggle to generate profit from its equity base.

Cash Flow

Cash flow analysis reveals persistent negative free cash flow, though operating cash flow has shown some improvement in recent periods. The free cash flow to net income ratio remains unfavorable, suggesting that the company is facing challenges in converting profits into cash.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
3.63M	3.73M	2.66M	2.51M	3.86M	3.48M
	Gross Profit
3.04M	3.12M	-1.03M	-1.21M	781.70K	458.00K
	EBIT
-2.70M	-2.38M	-2.92M	-2.61M	-1.43M	-1.80M
	EBITDA
-2.09M	-1.51M	-2.53M	-1.84M	-833.84K	-672.88K
	Net Income Common Stockholders
-2.36M	-2.07M	-2.59M	-1.97M	-924.24K	-1.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.48M	2.52M	2.18M	4.70M	1.71M	1.92M
	Total Assets
5.50M	5.13M	5.18M	7.99M	5.33M	5.92M
	Total Debt
1.60M	989.28K	1.09M	1.31M	1.43M	1.62M
	Net Debt
115.47K	-1.53M	-787.15K	-376.91K	-265.40K	-288.21K
	Total Liabilities
2.38M	2.07M	2.14M	2.06M	2.26M	2.50M
	Stockholders Equity
3.12M	3.06M	3.04M	5.94M	3.08M	3.42M
Cash Flow		Free Cash Flow
-1.52M	-1.22M	-1.58M	-1.08M	21.63K	-321.38K
	Operating Cash Flow
-1.51M	-1.16M	-1.42M	-967.51K	54.98K	-283.23K
	Investing Cash Flow
-56.85K	-57.55K	-151.94K	-115.31K	-33.35K	-38.16K
	Financing Cash Flow
536.63K	1.57M	-952.96K	4.05M	-281.87K	1.03M

Uscom Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Neutral. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.05 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:UCM.

Uscom Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
UCM	46 Neutral	AU$5.01M	―	-117.20%	―	2.91%	13.51%
1I4		€4.50M	―	-321.94%	―	―	―
ADR	47 Neutral	AU$5.31M	―	-375.15%	―	-59.01%	17.06%
CBL	41 Neutral	AU$10.31M	―	-98.08%	―	-7.44%	30.34%
AT1	39 Underperform	AU$10.98M	―	-61.15%	―	35.63%	18.55%
IRX	38 Underperform	AU$8.54M	―	-191.40%	―	―	19.74%

Uscom Limited Corporate Events

Uscom Limited Reports Increased Revenue Amid Global Challenges

Uscom Limited released its quarterly cash report for the period ending March 31, 2025, showing a 14% increase in customer receipts compared to the previous quarter, despite a challenging global trade environment. The company’s operational highlights include significant clinical achievements, strengthened partnerships with Foxconn and SinoPharm, and the establishment of a new subsidiary in China to support expansion. With new products and strategic partnerships, Uscom is well-positioned for growth in anticipation of a more stable global economic environment.